ATAI

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

• Lilly agreed to acquire AtaiBeckley to advance treatments for resistant depression and other mental health disordersJul 16, 2026
• AtaiBeckley announced additional Phase 2a results for EMP-01 showing strong and consistent improvements in social anxiety disorderApr 22, 2026
• BPL-003 showed rapid and durable antidepressant effects in Phase 2a data for treatment-resistant depressionApr 8, 2026
• AtaiBeckley reported positive topline results from an exploratory Phase 2a trial of EMP-01 (oral R-MDMA) in social anxiety disorderFeb 26, 2026
• AtaiBeckley announces new U.S. patent for EMP-01 strengthening IP portfolioDec 11, 2025